Mode of action of docetaxel - A basis for combination with novel anticancer agents

Cancer Treatment Reviews

Volumn 29, Issue 5, 2003, Pages 407-415

  Herbst, Roy S ^a   Khuri, Fadlo R ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Combination chemotherapy; Docetaxel; Mechanism; Novel agents

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; ANGIOGENESIS INHIBITOR; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURIDINE; GEFITINIB; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; OBLIMERSEN; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TIPIFARNIB; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; MICROTUBULE; MONOTHERAPY; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

EID: 0141725730     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00097-5     Document Type: Article

References (77)

1. Bissery MC. Preclinical pharmacology of docetaxel. Eur J Cancer 1995; 31A(Suppl 4): S1-6.
2. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288-291.
3. Riou JF, Naudin A, Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 1992; 187: 164-170.
4. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 1995; 6: 339-368.
5. Michaud LB, Valero V, Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 2000; 23: 401-428.
6. Crown J, O'Leary M. The taxanes: an update. Lancet 2000; 355: 1176-1178.
7. Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer. Drugs 2000; 59: 621-651.
8. Kaye SB and the Scottish Gynaecological Cancer Trials Group. The integration of docetaxel into first-line chemotherapy for ovarian cancer. Int J Gynecol Cancer 2001; 11(Suppl 1): 31-33.
9. Petrylak DP. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol 2000; 27(Suppl 3): 24-29.
10. Posner MR. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs 2001; 12(Suppl 1): 21-24.
11. Ridwelski K, Gebauer T, Fahlke J, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001; 12: 47-51.
12. Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin Oncol 2001; 28(Suppl 2): 4-9.
13. Rowinsky EK, Donehower RC. Antimicrotubule agents. In: Chabner BA, Longo DL (eds.), Cancer chemotherapy and biotherapy. 2nd ed. Lippincott-Raven: Philadelphia, 1996; 263-296.
14. Diaz JF, Valpuesta JM, Chacon P, Diakun G, Andreu JM. Changes in microtubule protofilament number induced by Taxol binding to an easily accessible site. Internal microtubule dynamics. J Biol Chem 1998; 273: 33803-33810.
15. Andreu JM, Diaz JF, Gil R, et al. Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain. J Biol Chem 1994; 269: 31785-31792.
16. Guéritte-Voegelein F, Guénard D, Lavelle F, Le Goff MT, Mangatal L, Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991; 34: 992-998.
17. Bernard C, Fellous A, Di Leo A, et al. Evaluation of microtubule associated parameters (MTAPs) as predictive markers for advanced breast cancer (ABC) patients treated with docetaxel. Eur J Cancer 2001; 37(Suppl. 6): 182.
18. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999; 44: 355-361.
19. Renehan AG, Booth C, Potten CS. What is apoptosis, and why is it important?. BMJ 2001; 322: 1536-1538.
20. Schimming R, Mason KA, Hunter N, Weil M, Kishi K, Milas L. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 1999; 43: 165-172.
21. Pratesi G, Perego P, Zunino F. Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy. Biochem Pharmacol 2001; 61: 381-386.
22. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by Bcl-2 antisense therapy. Lancet 2000; 356: 1728-1733.
23. Haldar S, Basu A, Croce CM. Bcl-2 is the guardian of microtubule integrity. Cancer Res 1997; 57: 229-233.
24. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995; 92: 4507-4511.
25. Haldar S, Chintapalli J, Croce CM. Taxol induced Bcl-2 phosphorylation and death in prostate cancer cells. Cancer Res 1996; 56: 1253-1255.
26. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999; 59: 3776-3782.
27. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253-270.
28. Kirsch M, Schackert G, Black PM. Angiogenesis, metastasis, and endogenous inhibition. J Neurooncol 2000; 50: 173-180.
29. Netti PA, Hamberg LM, Babich JW, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci USA 1999; 96: 3137-3142.
30. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 2000; 5(Suppl 1): 20-27.
31. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61: 3369-3372.
32. Vacca A, Ribatti D, Iurlaro M, et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 2002; 11(1): 103-118.
33. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000; 19: 6122-6129.
34. Linderholm BK, Lindh B, Beckman L, et al. The prognostic value of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) and associations to first metastasis site in 1307 patients with primary breast cancer. Proc Am Soc Clin Oncol 2001; 20: 13.
35. Moos PJ, Fitzpatrick FA. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 1998; 95: 3896-3901.
36. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001; 7: 584-590.
37. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-250.
38. Nagy P, Jenei A, Damjanovich S, Jovin TM, Szöllôsi J. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res 1999; 5: 255-271.
39. Wikstrand CJ, Bigner DD. Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-α. J Natl Cancer Inst 1998; 90: 799-801.
40. Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-832.
41. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37(Suppl 4): 9-15.
42. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
43. Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 1992; 12: 419-425.
44. Johnston SR, Kelland LR. Farnesyl transferase inhibitors - a novel therapy for breast cancer. Endocr Relat Cancer 2001; 8: 227-235.
45. Smith CA, Pollice AA, Gu LP, et al. Correlations among p53, HER2/neu and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer; evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. Clin Cancer Res 2000; 6: 112-126.
46. Theillet C, Lidereau. R, Escot C. Frequent loss of H-ras allele correlates with aggressive human primary breast carcinomas. Cancer Res 1986; 46: 4776-4781.
47. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992; 89: 6403-6407.
48. Johnson DH, DeVore R, Kabbinavar F, Herbst R, Holmgren E, Novotny W. Carboplatin (C) + paclitaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc Am Soc Clin Oncol 2001; 20: 1256.
49. Baselga J. Clinical trials of Herceptin® (trastuzumab). Eur J Cancer 2001; 37(Suppl. 1): 18-24.
50. Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 2001; 28(Suppl. 3): 20-27.
51. Pegram MD. Docetaxel and herceptin: foundation for future strategies. Oncologist 2001; 6(Suppl 3): 22-25.
52. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001; 28(Suppl 3): 13-19.
53. Kuzur ME, Albain KS, Huntington MO, et al. A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2. Proc Am Soc Clin Oncol 2000; 19: 512.
54. Burris 3rd HA. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001; 28(Suppl 3): 38-44.
55. Uber KA, Nicholson BP, Thor AD, et al. A phase II trial of weekly docetaxel (D) and herceptin (H) as first- or second-line treatment in HER2 overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20: 1949.
56. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2 overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 1800-1808.
57. Meden H, Beneke A, Hesse T, Novophashenny I, Wischnewsky M. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (Herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study. Anticancer Res 2001; 21: 1301-1305.
58. Nabholtz JM, Pienkowski T, Northfelt D, et al. Results of two open label multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (cis or carboplatin) (TCH) as therapy for advanced breast cancer (ABC) in women with tumours overexpressing the HER2-neu proto-oncogene. Eur J Cancer 2001; 37(Suppl 6): 190.
59. Pienkowski T, Fumuleau P, Eiermann W, et al. Taxotere, cisplatin and Herceptin (TCH) in first-line HER-2 positive metastatic breast cancer (MBC) patients: a phase II pilot study by the Breast Cancer International Research Group (BCIRG 101). Proc Am Soc Clin Oncol 2001; 20: 2030.
60. Slamon DJ, Patel R, Northfelt D, et al. Phase II pilot study of Herceptin combined with Taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER-2-neu proto-oncogene: a pilot study of the UCLA Network. Proc Am Soc Clin Oncol 2001; 20: 193.
61. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002; 29(1 Suppl 4): 27-36.
62. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000; 60(Suppl 1): 25-32.
63. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60(Suppl 1): 15-23.
64. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001; 37(Suppl 4): 16-22.
65. Kim ES, Mauer AM, Fossella FV, et al. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21: 1168.
66. Moasser MM, Sepp-Lorenzino L, Kohl NE, et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998; 95: 1369-1374.
67. Khuri FR, Glisson BS, Meyers ML, et al. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumours: dose finding, pharmacokinetics, efficacy/safety. Proc Am Soc Clin Oncol 2000; 19: 799.
68. Piccart MJ, Branle F, de Valeriola M, et al. A phase I, clinical and pharmacokinetic (PK) trial of the Farnesyl Transferase Inhibitor (FTI) R115777 + Docetaxel: a promising combination in patients (PTS) with solid tumours. Proc Am Soc Clin Oncol 2001; 20: 318.
69. Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 2001; 7: 1079-1086.
70. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub J-P, Cervantes G, Fumoleau P, Jones S, Lui W-Y, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20(12): 2812-2823.
71. Leonard R, Cervantes G, Lui W-Y, et al. Survival update of SO14999 - a large phase III trial of capecitabine/docetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). Eur J Cancer 2001; 37(Suppl 6): 151.
72. Pagani O, Sessa C, Longhi S, et al. Dose-finding study of docetaxel (T) and doxorubicin (A) day 1 and 8 plus capecitabine (X) day 1 to 14 (TAX) as first line treatment in advanced breast cancer (ABC). Eur J Cancer 2001; 37(Suppl 6): 194.
73. Khuri FR, Kurie JM. Antisense approaches enter the clinic. Clin Cancer Res (Ed) 2000; 6(5): 1607-1610.
74. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812-1823.
75. Hayes DF, Chen, HX, Marshall JL, Lippman D, Figuera M, Fingert H. G3139 (oligonucleotide antisense against bcl-2) and docetaxel in patients with Bcl-2-positive malignancies. In: American Society of Clinical Oncology, 37th Annual Meeting; 12-15 May 2001; San Francisco, CA, USA. Symposium: beyond chemotherapy - emerging targeted therapies for the treatment of cancer.
76. Morris MJ, Tong WP, Cordon-cardo C, et al. BCL-2 antisense (G3139) plus docetaxel for treatment of progressive androgen-independent prostate cancer. Eur J Cancer 2001; 37(Suppl 6): 218.
77. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000; 5(Suppl 1): 3-10.